05:01:33 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaFirst North Stockholm
Bio-Works Technologies är verksamma inom bioteknik. Bolaget utvecklar produkter som separerar och renar molekyler vid framställning av läkemedel. Teknologin baseras på kromatografi som har som avsikt att hantera läkemedelssubstansen. Kunderna återfinns inom den europeiska marknaden där produkterna säljs via distributionspartners och till bolag inom läkemedelsindustrin, samt forskningsinstitut och universitet. Bolaget bildades 2006 och har sitt huvudkontor i Uppsala.


2023-02-17 Bokslutskommuniké 2022
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-23 Ordinarie utdelning BIOWKS 0.00 SEK
2022-05-20 Årsstämma 2022
2022-02-18 Bokslutskommuniké 2021
2021-11-25 Extra Bolagsstämma 2021
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-24 Ordinarie utdelning BIOWKS 0.00 SEK
2021-05-21 Årsstämma 2021
2021-02-19 Bokslutskommuniké 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-18 Ordinarie utdelning BIOWKS 0.00 SEK
2020-05-15 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-10-18 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-27 Ordinarie utdelning BIOWKS 0.00 SEK
2019-05-17 Årsstämma 2019
2019-04-29 Kvartalsrapport 2019-Q1
2019-02-22 Bokslutskommuniké 2018
2018-08-19 Kvartalsrapport 2018-Q2
2018-05-21 Ordinarie utdelning BIOWKS 0.00 SEK
2018-05-18 Årsstämma 2018
2018-02-19 Bokslutskommuniké 2017
2022-04-21 07:24:45
Bio-Works Technologies. Update Q1-2022. Today, Bio-Works Technologies AB reports sales for the first quarter of 2022—a strong quarter in line with the company’s plan. Product sales reached 6.0 MSEK, an increase of 135% as compared to the same period one year ago. Backlog increased to 8.4 MSEK, from 6.9 MSEK at the start of the year.

”We are very happy with our performance in Q1,” said Jonathan Royce, CEO at Bio-Works.

”Sales growth continues to increase according to plan and we have added new customers in the US, India and Europe during the past three months. Our backlog at the start of the second quarter puts in a very good position for the first half of 2022, and there is nothing which indicates that our momentum is going to slow during the second half.”

Bio-Works sales increased fastest in North America to 3.2 MSEK (0.2 MSEK) with new orders from Northern RNA, Catalent Pharma and a new process customer, KBI Biopharma. Asia also increased to 0.8 MSEK (0.3 MSEK), led by a new order from Reliance Life Sciences in India.

Agreements with new distributors in Ireland and Northern Ireland, as well as in France, have been reached during the quarter with Brennan & Co. and Ozyme SAS, respectively. These distributors increase Bio-Works’ reach and provide opportunities to build strong relations and to offer customers local support. Ireland and France are important markets in Europe, and there is good potential for Bio-Works to further increase its sales via these distribution agreements.

In February, Bio-Works’ quality management system was audited by Intertek, an external certification organization. In March, the company received an approval and re-certification, which means that the management system fulfills the requirements for the international standard ISO 9001:2015. The standard is a harmonized standard in the EU, and an approved certificate is evidence of the company’s ability to consistently deliver products which fulfill customer requirements and applicable legal standards.  

During the second quarter, Bio-Works is planning for a new product launch to increase its offering of so-called “pre-packed” columns. These products are turnkey solutions for pharma companies who want to save time in production.

”The global market for prepacked columns is dominated by a few players and is plagued by long lead times coupled with a high customer demand. We believe that our launch is going to attract more new customers who will discover both Bio-Works as a supplier and our exceptional chromatography resins,” said Royce.  

This disclosure contains information that Bio-Works Technologies AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 21-04-2022 07:24 CET.